Development of comprehensive disease assessment in systemic vasculitis

…, N Rasmussen, P Seo, K Westman… - Postgraduate …, 2008 - academic.oup.com
The systemic vasculitides are multisystem disorders with considerable mortality and
morbidity and frequent relapses. In the absence of reliable serological markers, accurate …

Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical …

…, DGI Scott, RA Watts, P Höglund, K Westman… - Annals of the …, 2011 - ard.bmj.com
Objectives Because standard immunosuppressive treatment for antineutrophil cytoplasm
antibody-associated vasculitis (AAV)(granulomatosis with polyangiitis (Wegener's)(GPA) …

[HTML][HTML] A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies

…, C Siegert, A Sinico, V Tesar, K Westman… - … England Journal of …, 2003 - Mass Medical Soc
Background The primary systemic vasculitides usually associated with autoantibodies to
neutrophil cytoplasmic antigens include Wegener's granulomatosis and microscopic …

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis

…, M Segelmark, V Tesar, K Westman… - Annals of the …, 2016 - ard.bmj.com
In this article, the 2009 European League Against Rheumatism (EULAR) recommendations
for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis …

[HTML][HTML] Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis

…, D Walsh, M Walsh, K Westman… - … England Journal of …, 2010 - Mass Medical Soc
Background Cyclophosphamide induction regimens for antineutrophil cytoplasmic antibody
(ANCA)–associated vasculitis are effective in 70 to 90% of patients, but they are associated …

EULAR recommendations for the management of primary small and medium vessel vasculitis

…, DGI Scott, C Stegeman, R Watts, K Westman… - Annals of the …, 2009 - ard.bmj.com
Objectives: To develop European League Against Rheumatism (EULAR) recommendations
for the management of small and medium vessel vasculitis. Methods: An expert group …

Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis

DRW Jayne, G Gaskin, N Rasmussen… - Journal of the …, 2007 - journals.lww.com
Systemic vasculitis associated with autoantibodies to neutrophil cytoplasmic antigens
(ANCA) is the most frequent cause of rapidly progressive glomerulonephritis. Renal failure …

Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody—associated vasculitis: a randomized trial

…, RA Sinico, V Tesar, P Vanhille, K Westman… - Annals of internal …, 2009 - acpjournals.org
Background: Current therapies for antineutrophil cytoplasmic antibody (ANCA)–associated
vasculitis are limited by toxicity. Objective: To compare pulse cyclophosphamide with daily …

Long-term patient survival in ANCA-associated vasculitis

…, C Stegeman, M Walsh, K Westman… - Annals of the …, 2011 - ard.bmj.com
Background Wegener's granulomatosis and microscopic polyangiitis are antineutrophil
cytoplasm antibodies (ANCA)-associated vasculitides with significant morbidity and …

EULAR recommendations for the management of large vessel vasculitis

…, DGI Scott, C Stegeman, R Watts, K Westman… - Annals of the …, 2009 - ard.bmj.com
Objectives: To develop European League Against Rheumatism (EULAR) recommendations
for the management of large vessel vasculitis. Methods: An expert group (10 …